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Abstract
Background/Aim. Autogenous bone grafting has been
the gold standard in clinical cases when bone grafts are
required for bone defects in dentistry. The study was un-
dertaken to evaluate multilevel designed carbonated hy-
droxyapatite (CHA) obtained by hydrothermal method, as
a bone substitute in healing bone defects with or without
corticosteroid treatment in rats as assessed by histo-
pathologic methods. Methods. Bone defects were created
in the alveolar bone by teeth extraction in 12 rats. The
animals were initially divided into two groups. The ex-
perimental group was pretreated with corticosteroids:
methylprednisolone and dexamethasone, intramuscularly,
while the control group was without therapy. Posterior
teeth extraction had been performed after the cortico-
steroid therapy. The extraction defects were fulfilled with
hydroxyapatite with bimodal particle sizes in the range of
50–250 m and the sample from postextocactional defect
of the alveolar bone was analyzed pathohystologically.
Results. The histopatological investigations confirmed
the biologic properties of the applied material. The evi-
dent growth of new bone in the alveolar ridge was clearly
noticed in both groups of rats. Carbonated HA obtained
by hydrothermal method promoted bone formation in the
preformed defects, confirming its efficacy for usage in
bone defects. Complete resorption of the material’s parti-
cles took place after 25 weeks. Conclusion. Hydroxyapa-
tite completely meets the clinical requirements for a bone
substitute material. Due to its microstructure, complete
resorption took place during the observation period of
the study. Corticosteroid treatment did not significantly
affect new bone formation in the region of postextrac-
tional defects.
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Apstrakt
Uvod/Cilj. Autogeni koštani graftovi predstavljaju zlatni
standard u stomatologiji za popunjavanje koštanih defe-
kata. Studija je sprovedena kako bi se ispitala efikasnost vi-
šefaznog karbonatnog hidroksiapatita (HA), dobijenog hi-
drotermalnam metodom, kao zamene za kost kod in vivo
zarastanja koštanih defekata. Procena efikasnosti izvršena
je patohistološkom analizom na pacovima (Sprague
Dawley). Metode. Koštani defekti naÿinjeni su u alveolar-
noj kosti ekstrakcijom boÿnih zuba kod 12 pacova. Ekspe-
rimentalne životinje prvo su bile podeljene u dve grupe.
Prva, kontrolna grupa, bila je bez terapije, dok je druga,
eksperimentalna grupa intramuskularno dobijala kortikos-
teroidnu terapiju i to metilprednizolon i deksametazon.
Ekstrakcija boÿnih zuba izvršena je nakon resorpcije izaz-
vane terapijom kortikosteroidima. Ekstrakcione rane ispu-
njene su hidroksiapatitom ÿestica veliÿine 50–250 m, a
uzorci uzeti iz postekstrakcionih defekata alveolarne kosti
analizirane su patohistološki. Rezultati. Patohistološkom
analizom potvrĀena su biološka osteokonduktivna svojstva
primenjenog materijala. Intenzivni rast nove kosti unutar
alveolarnog grebena jasno je uoÿen u obe grupe eksperi-
mentalnih životinja. Karbonatni HA dobijen hidrotermal-
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nim metodom inicirao je formiranje kosti preko površine
defekata, potvrĀujuýi efikasnost njegove primene kod ko-
štanih defekata. Do potpune resorpcije materijala došlo je
posle 25 nedelja. Zakljuÿak. Ispitivani hidroksiapatit u
potpunosti zadovoljava kliniÿke zahteve kao zamena za
kost, poštujuýi ograniÿenja eksperimentalne namene stu-
dije. Zbog mikrostrukture materijala došlo je do komplet-
ne resorpcije tokom perioda posmatranja.  Leÿenje korti-
kosteroidima nije znaÿajno uticalo na stvaranje nove kosti
u predelu potekstrakcionih defekata.
Kljuÿne reÿi:
zub, ekstrakcija; alveolna kost, gubitak; graftovi;
pacovi; hidroksiapatiti; kortikosteroidni hormoni.
Introduction
Autogenous bone grafting has been the gold standard in
clinical cases when bone grafts are required for bone defects
in dentistry. The proven advantages of autogenous bone
grafting are: osteogenic potential, satisfactory mechanical
properties and the absence of adverse immunological re-
sponse 1, but there are also some limitations, such as: re-
quirement of additional surgery for harvest, reduced avail-
ability of adequate quantity and quality of graft material and
the risk of patient morbidity 2–4. In order to overcome these
disadvantages, many kinds of synthetic biomaterials have
been developed as bone substitutes, such as hydroxyapatite
(HA), alumina, zirconia, bioglass, polymers, metal, and or-
ganic or inorganic bone substitutes 5–7.
For biomedical indications, HA has been used exten-
sively as a substitute in bone grafts 5, because the natural bone
is similar to HA. From the 1980s to nowadays, various forms
of HA have been used in orthopaedic, dental or maxillofacial
surgery 5, 6. For specific form of HA, carbonated calcium hy-
droxyapatite [CHA; Ca10(PO4)6-xCO3x(OH)2], osteoconductive
properties have been proven 8. Osteoconductive properties are
significantly dependent on the porous structure of CHA, sur-
face area, morphology and size of its particles. Furthermore, it
has been shown that the CHA is bioresorbable and more bio-
active than stoichiometric HA 4, 5, 9, 10.
The mechanism of glucocorticoid effect on bone me-
tabolism is rather complex, and its role in arresting wound
healing is not clearly described. Glucocorticoids modify os-
teoblastic cell differentiation, their number and function, thus
inhibiting bone formation 11. Inhibition of bone formation is
simultaneously followed by bone resorption and subsequent
bone loss. When administered for prolonged periods, gluco-
corticoid therapy is inevitably associated with bone loss, ar-
rested osteoblast activity and suppressed bone formation via
the osteoclasts 12. Data regarding the influence of corticoster-
oid therapy on the teeth extraction wound healing are scarce.
After surgical procedure of tooth extraction, a coagu-
lum fulfils the alveolar socket and a process of wound heal-
ing occurs. The healing never allows ad integrum restitution
of the alveolar bone ridge, resulting in decreased bone vol-
ume and physiological resorption. Bone resorption leads to a
decrease of height and width of the alveolar ridge which is a
significant clinical problem 13. Socket preservation is a pro-
cedure in which graft material is placed into the alveolar
socket of an extracted tooth at the time of extraction in order
to maintain the volume of the alveolar ridge 14. For this pur-
pose, various techniques and materials have been employed,
such as alloplast materials, autogenous bone, allograft bone,
atraumatic extraction, immediate placement of dental im-
plants or immediate socket filling with osteoconductive ma-
terial. In recent years synthetic bone substitutes based on HA
are frequently used for this particular clinical indication and
are considered as promising materials due to their physical
properties and similarity to natural bone.
The aim of the study was to assess the efficacy of hy-
drothermally obtained CHA in healing alveolar bone defects
in rats with or without corticosteroid therapy.
Methods
Precursors for CHA synthesis were prepared as follows:
chicken egg shells were calcined at 900 °C till complete car-
bon removal and dissociation of CaCO3 to CaO. The second
precursor was Merk’s pro analysis quality (NH4)2HPO4. A
total of 500 mL of 2.32 cmol (NH4)2HPO4 solution was
poured into 500 mL of 3.02 cmol Ca(OH)2 solution and
thoroughly mixed. In the end, 0.1 N HCl and (NH4)OH were
added to buffer the pH value of the solution to 7.4 according to
the methodology previously described by Jokanoviü et al. 15, 16.
This mixture was covered using a glass plane and put into the
autoclave at 150° C and pressure up to 10 bar for 8 h.
After hydrothermal treatment in the autoclave, precipi-
tates were decanted from glasses and dried at 80° C during
the period of 48 h, disintegrated, rinsed with deionized water,
and centrifuged with the purpose to get the purest possible
CHA. After the process of characterization, hydrothermally
obtained CHA particles were put into the glass pipettes and
sterilized using gamma rays with the dose of 25 Gy.
Animal model and surgical procedure
The experiment was conducted according to the Good
Laboratory Practice (GLP) at the Faculty of Dentistry, Univer-
sity of Belgrade, with tried and tested experimental facilities.
A total of 12, 6–8-week-old, 250–275 g weighty, syn-
geneic female Sprague Dawley rats who had attained sexual
maturity, were used in the study. Rats were housed 4 per
cage with water and food at will. The animals were put in
quarantine for at least 10 days prior to intervention. The
animals were initially divided into 2 groups. The experi-
mental group was treated with intramuscular glucocorticoids:
methylprednisolone (Lemond-Solu®, Hemofarm, Vrsac, Ser-
bia) and dexametosane (Dexason®, Galenika, Belgrade, Ser-
bia). The control group was without corticosteroid therapy.
The dose of glucocorticoids was 2 ȝg/g of body mass. Both
medicines were given every second day. The teeth extraction
from posterior region was performed after the corticosteroid
therapy. The extraction defects were fulfilled with the CHA
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with bimodal particle sizes in the range of 50–100 m and
200–250 m. The surgical procedure was performed under
general anaesthesia using a halogenous compound, oxy-
gen/isoflurane (Forane R®, Abbott Laboratories, Abbott
Park, Illinois, USA).
About 0.3 g on average of CHA was put into created
wounds with approximately equal diameters and depth of
about 0.5 mm. No antibiotic treatment was administrated af-
ter the surgical procedure. The animals were sacrificed 5, 15
and 25 weeks after surgery using mechanism of an intracar-
diac overdose with sodium pentobarbital (Dolethal®, Veto-
quinol, Lure, France).
The sample for histopathological analysis was the al-
veolar bone from the region of the artificial postextractional
defect of the jaw. The bone was rinsed with a physiological
solution, fixed with 10% formalin and decalcified by elec-
trolysis in a solution of concentrated formic acid during the
period of 10–12 h. After decalcination, dehydration of the
tissue was performed using ethanol solution. Finally, all
samples were formed in paraplast, cut using microtome and
colored by hemotoxylin-eosin (HE) method.
The histological preparations were histopathologically
analyzed by an image analysis software, Lucia 32G (Labo-
ratory Imaging, Prague, Czech Republic) on a microscope
(LEICA DMR) with 10u magnification (NA = 0.5) and a
digital camera (with 640 u 480 pixels).
Results
The signs of the initial osteogenesis were clearly ob-
served in both groups. For animals treated with intramuscu-
lar glucocorticoids, the remnants of the implanted materials
sized between 200 and 250 m were visible 5 weeks after
implantation of CHA. The interposed capillars, vascular
structures and cells typical for a young bone were clearly ob-
served (Figure 1a). Similarly, for the group without therapy,
intergrowth of the capillary within the implanted material
was evident 5 weeks after the implantation of CHA (Figure
1b). The average particles size of the implanted material in
the control group was less than 200 m.
Fifteen weeks after implantation, infiltration of the im-
planted CHA with blood vessels and osteoblasts migrating
from the surrounding bone was slightly more intensive in the
control group. It was evident that the new bone more inten-
sively fulfilled the defects, transforming the CHA granule
into a new bone. Remodulation processes in the alveolar de-
fects were observed (Figure 1c). For the control group, the
implanted material was saturated by blood capillary and os-
teoblasts from the surrounding bone as well. Defects were
partially fulfilled with newly formed bone (Figure 1d).
After 25 week, implanted CHA was substituted com-
pletely by new immature bone in the control group. In the
center of the defect, bone slowly became mature, while bone
structure fulfilled almost complete defect. The complete in-
tegration of the new and existing bone tissue at the connec-
tive lines was almost completed in numerous spots (Figure
1f). In the experimental group, defects in the alveolar bone
were fulfilled almost completely by the new bone tissue.
When compared with the control group signs of slightly less
intensive bone maturation were noticed, and the bone struc-
ture was slightly more irregular. (Figure 1e).
Fig. 1 – a, b) Five weeks after implantation of hydrother-
mally obtained carbonated hydroxyapatite (CHA), evident
intergrowth of the capillary started inside the implanted ma-
terial. The beginning of the initial osteogenesis was visible in
both groups; c, d) Fifteen weeks after implantation, the im-
planted material (CHA) was saturated by blood capillary
and osteoblasts (BC) from the surrounding bone (black ar-
row). The bony defect (BD) was partially fulfilled with a new
bone (dotted arrow); e, f) Twenty five weeks after implanta-
tion, alveolar bone defects were fulfilled almost completely
by new bone in both groups. Slightly more intensive osteo-
genesis was noticed in the control group. The integration of
new and existing bone tissue was almost completed in the
numerous spots.
Discussion
Nanostructured bone substitutes such as CHA particles
with a high surface area are desirable in many fields includ-
ing tissue engineering. The synthesis of nanostructured CHA
was mostly based on the precipitation reaction developed by
Nelson and Featherstone which was described in details by
Barralet et al. 9. Hasegawa et al. 10 have also successfully
produced sintered CHA which can be resorbed by osteoclasts
both under in vitro and in vivo conditions, while classic sin-
tered stoichiometric CHA cannot be resorbed. Apart from
particle size and size distribution, the shape of bioactive and
reinforcing particles are also important when developing
bioactive bone substitute materials based on HA (porous or
non-porous) for human tissue repair 10, 17.
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Besides the better mechanical properties of sintered ma-
terials obtained from nanosized CHA, Evis et al. 18 reported
faster osteoblast proliferation and greater osteoclast activity on
nano-CHA in comparison with the conventional CHA, which
has micron grain sizes. It was proven that in extracellular cul-
ture the synthesis of alkaline phosphatase by osteoblast on
nano-CHA was faster than on the conventional micron grain
size CHA 8. The nano-CHA integrated in the structure of bone
defects also has better osteointegrative properties. Therefore, it
could be assumed that CHA with nanosized basic particles in-
tegrated in the granule design similar to natural bone would
exhibit better biocompatibility 19, 20.
In the present investigation, a longer observation period
of 25 weeks following surgery may be a factor of complete
CHA reabsorption. In addition, very fine particle size and the
small level of impurities in our CHA can act as catalysts of
CHA biological activity, and contribute to the significant re-
absorption.
A special structure of hydrothermally obtained hy-
droxyapatite and its potential very high surface activity
caused by its nanometric size of apatite crystallite and very
small particle size were the basis for the expectation of its
substantially improved osteogenic activity on the site of bone
defect 19, 20. The pores within the material, sized about 200
m, cylindrically shaped, and located inside of a CHA gran-
ule, have dimension which may enable the proliferation of
young connective tissue and provide the environment for
osteoblast cell activity expression. It may be assumed that a
very small size of CHA crystallites (several nanometers)
strongly promoted boundary activity of osteogenic cells with
CHA. In the present study, the result of these processes was
the higher rate of CHA disintegration, its transformation and
osteointegration into a new bone, even in the group of ex-
perimental animals that were submitted to the corticosteroid
treatment.
The structure of CHA and its pore distribution is mul-
timodal and follows not only the size of the primary parti-
cles, the smallest ones, but also the size of the other particles
packed into the clustered powder particles. The pores are
distributed from the smallest ones in the range of 1.5–15 m
up to the largest with the range of 50–250 m. The largest
pores correspond to the largest particles approximately 250
m in size, clustered mostly into agglomerated particles 1–5
ȝm large, which can be seen in SEM micrographs of synthe-
sized CHA, as previously described in detail in the study by
Jokanoviü et al. 16. These particles are finally joined in the
granules with the diameter between 300 ȝm and 1000 ȝm.
In the present investigation, the osteogenic potential of
CHA was evaluated with regard to corticosteroid treatment.
Therefore, the experiments with the rats previously treated
with corticosteroid therapy were made, similarly to the pre-
viously conducted research 21. These animals were compared
with 6–8-week-old healthy Sprague Dawley rats that attained
sexual maturity in which bone mineralization process had
been completed. The morphology of postextractional wound
healing of the alveolar bone was investigated. The process of
new bone formation inside of the defect area was observed in
order to compare it with bone formation in the control group
of animals. Newly formed bone with obvious evidences of
mature bone characteristics were noticed 25 weeks after im-
plantation in both investigated experimental groups. Inside
healthy bone, it was obvious that healing was going on rap-
idly and very efficiently without any additional stimulation
of osteogenesis 21–24.
In the experimental group of animals, it was noticed
that osteointegration of bone tissue had begun, but that this
process is in the starting phase. The rate of the process of
intergrowth of blood capillarity and activation of the osteo-
blast was more intensive for the control group of animals
during the same observation period.
Opposite, in the subgroup where CHA was implanted
for a longer time, in both groups of animals the intensive
formation of new bone, increased binding, as well as migra-
tion and distribution of blood vessels and osteogenic cells
within the remnants of implanted material were noticed,
which confirmed the CHA osteoconductive effect 25.
A significantly higher rate of osteogenesis in rats with-
out corticosteroid treatment, in comparison to the control
group, is probably caused by the activity of osteoblast cells
which accelerated not only their proliferation and differen-
tiation, but also the formation of new bone 26, 27.
According to the recently published investigations, the
bone morphogenetic protein can be produced as the basis for
the recruitment of mesenchymal stem cells in the region of
defect by means of hemotaxis, initiating further quick prolif-
eration and differentiation into chondroblasts and chondro-
cytes 21. These cells later enter the cartilage-like matrix,
which is calcified into bone. The final phase is the bone tis-
sue remodeling and formation of mature lamellar bone that
was clearly noticed in the present study.
Generally, the examined hydrothermally obtained CHA
exhibited strong osteoconductive effect, enabling formation
organization of osteons similar to normal bone. That is clear
evidence that hydrothermally obtained CHA has a potential
to form new bone and to replace bone tissue due to its osteo-
conductive properties. Therefore, hydrothermally obtained
CHA can be used for the surgical treatment of defects caused
by the resorption of alveolar bone ridge.
Conclusion
This histopathological investigation of hydroxyapatite
showed that the hydrothermally obtained carbonated hy-
droxyopatite has a potential to be applied as an osteoconduc-
tive material. The intensive growth of new bone tissue in the
compact jaw ridge was evidently approved. Corticosteroid
treatment did not significantly affect new bone formation in
the region of postextractional defects. The hydrothermally
obtained carbonated hydroxyapatite shows a significant po-
tential and efficiency for reparation, healing and preservation
of alveolar bone defects.
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